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as ≤21 beats during the first minute of recovery in a sitting position and 
found that abnormal HRR is sensitive with regard to the diagnosis of 
coronary artery disease (CAD) (76.1%) but does not exhibit good speci-
ficity (41.3%). We suggest that the presence of abnormal HRR (≤21 
beats) in treadmill exercise testing should be considered an additional 
diagnostic criterion for the presence of CAD, and therefore, we agree 
that HRR should be incorporated into the interpretation of treadmill 
exercise testing (TET), in addition to other significant parameters, such 
as ST-segment depression, typical chest pain, or hypotensive response. 
Normal parasympathetic reactivation is needed for the rapid decrease 
in heart rate following the cessation of exercise. Therefore, slow HRR after 
exercise has prognostic value for predicting cardiovascular mortality, 
regardless of the extent of coronary disease (2). However, several risk 
factors for atherosclerosis, especially metabolic syndrome components 
(3), advancing age (4), and chronic obstructive pulmonary disease (5), are 
important factors of decreased HRR. Because the risk factors mentioned 
above are also strongly associated with CAD, the calculation of HRR, as 
well as traditional markers of ischemic response during TET, could provide 
additional diagnostic information about the presence of CAD.
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Assessment of serum hepcidin levels 
in patients with non-ST elevation 
myocardial infarction
To the Editor,
We read the article, entitled “Assessment of serum hepcidin levels in 
patients with non-ST elevation myocardial infarction,” by Altun et al. (1) 
published in Anatolian J Cardiol 2014; 14: 515-8. Serum hepcidin levels 
were comparable among NSTEMI patients and control subjects. Also, 
its concentration did not change 6 hours after admission. The authors 
concluded that hepcidin could not be used as a marker of myocardial 
necrosis in NSTEMI patients. We thank the authors for drawing atten-
tion to a very important and challenging field of cardiology: markers in 
acute coronary syndromes. However, in their study, we think that there 
are some important questions that need to be answered.
The peptide hormone hepcidin is the main conductor of systemic 
iron hemostasis (2). The expression of the hepcidin gene has been 
shown to be regulated by hypoxia and inflammation (3). According to 
this finding, Suzuki et al. (4) argued that the human heart might also 
react to ischemia, and they measured serum hepcidin levels in patients 
with acute myocardial infarction. They found an elevated serum hepci-
din level within 4 hours after the heart attack and showed that hepcidin 
levels decreased to normal levels in 7 to 14 days. In the present study 
of Altun et al. (1) the time interval between the onset of the symptoms 
and blood sampling was not mentioned. Additionally, the authors 
retested serum samples of the NSTEMI patients only 6 hours later. 
However, hepcidin levels are detectable after several days following 
myocardial injury (4). The racial and genetic differences between the 
study population of Suzuki et al. (4) and Altun et al. (1) can explain the 
negative result of the latter study. The authors did not mention anything 
regarding coronary artery lesions of the study population; control sub-
jects were aged between 50 and 70 years, and they can also have coro-
nary atherosclerosis. Hence, it is an important limitation of this study if 
hepcidin might reflect destabilization of the coronary plaques, as 
expected from an inflammatory biomarker. The authors provided that 
CRP levels were increased in NSTEMI patients. In this point, performing 
a correlation analysis between CRP and hepcidin levels is very essen-
tial. In the case of showing this relationship, it could be argued that 
hepcidin might be a surrogate marker of inflammation, although plasma 
kinetics were not identified properly. Moreover, since this biopeptide is 
not a structural element of the myocardial cell like cardiac troponin I, it 
naturally might not be elevated at the same time. Finally, serum levels of 
hepcidin in patients and in control subjects were unevenly distributed: 
24.55±32.13 and 23.67±33.62 ng/mL. It can be concluded that there are 
many extreme cases in the laboratory results, which can affect all 
analyses and interpretations in this small-sized study. 
Therefore, we think that although the study conducted by Altun et 
al. (1) draws attention to a very important and interesting subject, there 
are several points in the study design and data evaluation that need to 
be discussed, and the study results should be interpreted with caution.
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Author`s Reply
To the Editor,
We thank you for your comments on our study published in the 
September 2014 issue of The Anatolian Journal of Cardiology entitled 
"Assessment of serum hepcidin levels in patients with non-ST elevation 
myocardial infarction (NSTEMI)." (1). They have raised some questions. 
Hepcidin is produced mainly in the liver and increases in response to 
inflammation, and its expression is regulated by anemia, hypoxia, and 
inflammation (2). In this single-center study, we evaluated whether the 
level of hepcidin increased in the acute phase in NSTEMI, known as 
acute inflammatory aggravation of a chronic atherosclerotic process.
There are conflicting results for hepcidin in coronary artery dis-
ease patients (3, 4). The first remark was about blood sampling time 
and symptom onset. We did not investigate hepcidin kinetics in this 
study; our aim was fundamentally to use hepcidin as a new cardiac 
marker instead of troponin. Another remark was about the time inter-
val between the onset of the symptoms and blood sampling. According 
to our study design, we aimed to compare hepcidin levels with tropo-
nin levels in the diagnosis of NSTEMI. It is important that the hepcidin 
levels did not increase; meanwhile, the levels of troponin were 
increased in NSTEMI patients in the acute phase. The observed dif-
ferences in these parameters, performed simultaneously from the 
same patients, forced us to think that there was no need to take the 
time interval between the onset of symptoms and blood sampling. The 
other remark was about the study of Suzuki et al. (4). The patient 
population and the design of the two studies were different, as the 
authors (4) studied ST elevation myocardial infarction patients, but we 
did not. Also, the sample of their study was extremely low, and their 
aim was also different. As stated in the criticism, if we performed a 
correlation analysis between CRP and hepcidin levels, it should have 
corroborated our results, showing hepcidin as a surrogate marker of 
inflammation.
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Transcatheter closure of antegrade 
pulmonary blood flow with Amplatzer 
septal occluder after Fontan operation
To the Editor,
We read the article of Karagöz et al. (1), entitled “Transcatheter 
closure of antegrade pulmonary blood flow with Amplatzer muscular 
VSD occluder after Fontan operation,” published in The Anatolian 
Journal of Cardiology 2014; 14: 565, with great interest. Recently, in our 
clinic, we closed residual antegrade pulmonary blood flow with an 
Amplatzer septal occluder device after Fontan operation.
Our patient’s initial diagnosis was unbalanced complete atrioven-
tricular septal defect and double outlet right ventricle with D-transposed 
great arteries. His first surgery was a pulmonary banding operation 
when he was 2.5 months old. When he was 6.5 years old, a bi-direction-
al Glenn operation was performed (with antegrade flow). He underwent 
an extracardiac Fontan operation at the age of 11 years in our clinic. 
During his hospital stay, 10 days after the Fontan procedure, massive 
pleural effusion, edema, and ascites were detected. Echocardiography 
revealed significant antegrade flow to the pulmonary artery. The patient 
underwent cardiac catheterization to close the antegrade flow. Mean 
pulmonary artery pressure was 33 mm Hg. The right ventriculogram and 
main pulmonary artery angiogram showed normally branched pulmo-
nary arteries, with a narrowing in the main pulmonary artery owing to 
his first operation-pulmonary banding. The narrow part of the pulmo-
nary artery was 9 mm, and the proximal and distal sides of this narrow 
part were 24.3 mm and 21.5 mm, respectively. An 11-mm Amplatzer 
septal occluder (AGA Medical, MN, USA) device was deployed at the 
narrow region. After deployment of the device, the mean pulmonary 
artery pressure decreased to 26 mm Hg, which was also high but at 
least lower than the pre-intervention pressure. 
Residual forward flow from the ventricle to the pulmonary artery, 
via either a native pulmonary outflow tract or a previously banded or 
ligated main pulmonary artery, leads to ineffective even hazardous 
pulmonary blood flow and unnecessary ventricular volume overload in 
Fontan patients. This in turn can lead to persistent pleural effusions or 
ventricular failure, especially in patients with transposed great arteries, 
in whom surgical dissection of the main pulmonary artery during the 
Fontan procedure would be difficult or hazardous. At least 5 of 8 
patients from the Desai et al. (2) series had transposed great arteries. 
Similarly, our case had transposed great arteries. It may be difficult to 
locate and close pulmonary antegrade flow due to the anatomy of the 
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